Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models

被引:4
作者
De Pablo-Moreno, Juan A. [1 ]
Liras, Antonio [1 ]
Revuelta, Luis [2 ]
机构
[1] Univ Complutense Madrid, Sch Biol, Dept Genet Physiol & Microbiol, Madrid, Spain
[2] Univ Complutense Madrid, Sch Vet Med, Dept Physiol, Madrid, Spain
关键词
factor V; prothrombin time; activated partial thromboplastin time; mouse; measurement standardization; transfusion; pathological models; factor V deficiency; HEMOPHILIA-A; PLASMA; TRANSFUSION; HEMORRHAGE; EVOLUTION; SELECTION;
D O I
10.3389/fvets.2022.846216
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Factor V together with activated factor X forms the prothrombinase complex, which transforms prothrombin into thrombin. The Mus musculus species is characterized by very high levels of this factor and short clotting times, which hinders accurate measurements. For that reason, a detailed characterization of such parameters is indispensable. A method was designed as part of this study to provide an accurate determination and standardization of factor V levels, prothrombin time and activated partial thromboplastin time in Mus musculus. Those parameters were evaluated in a sample of 66 healthy animals using a semi-automated coagulometer and human diagnostic reagents in an attempt to determine the most appropriate time of day for the extractions. A mouse-based protocol was designed, capable of making corrections to the samples at dilutions of 1:100 for factor V and at of 1:3 for prothrombin time. The goal was to smoothen the calibration curves, which often present with steep slopes and narrow measurement ranges between one calibration point and another. It was found that the most stable period for blood sample extraction was that comprised between the first 6 h of light. No clinical differences were observed between the sexes and reference intervals were established for factor V (95.80% +/- 18.14; 25.21 s +/- 1.34), prothrombin time (104.31% +/- 14.52; 16.85 s +/- 1.32) and activated partial thromboplastin time (32.86 s +/- 3.01). The results obtained are applicable to human or veterinary biomedical research, to transfusional medicine or to pathological models for diseases such as factor V deficiency.
引用
收藏
页数:10
相关论文
共 45 条
  • [31] Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
    Lawlor, Matthew
    Gupta, Aakriti
    Ranard, Lauren S.
    Madhavan, Mahesh V.
    Li, Jianhua
    Eisenberger, Andrew
    Parikh, Sahil A.
    Sethi, Sanjum S.
    Masoumi, Amirali
    THROMBOSIS RESEARCH, 2021, 198 : 79 - 82
  • [32] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    Cuker, A.
    Ptashkin, B.
    Konkle, B. A.
    Pipe, S. W.
    Whinna, H. C.
    Zheng, X. L.
    Cines, D. B.
    Pollak, E. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 80 - 86
  • [33] How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors
    Favaloro, Emmanuel J.
    Kershaw, Geoffrey
    Mohammed, Soma
    Lippi, Giuseppe
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (01) : 22 - 35
  • [34] Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A
    Gu, J-M.
    Ramsey, P.
    Evans, V.
    Tang, L.
    Apeler, H.
    Leong, L.
    Murphy, J. E.
    Laux, V.
    Myles, T.
    HAEMOPHILIA, 2014, 20 (04) : 593 - 600
  • [35] C-reactive protein-induced activated partial thromboplastin time prolongation in heparinized samples is attenuated by elevated factor VIII
    Kostousov, Vadim
    Devaraj, Sridevi
    Bruzdoski, Karen
    Hensch, Lisa
    Hui, Shiu-Ki
    Teruya, Jun
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (01) : 139 - 142
  • [36] von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study
    Munsanje, Miyoba Melinda
    Kaile, Trevor
    Kowa, Sumbukeni
    Sinkala, Musalula
    Simakando, Marah
    Ndhlovu, Jacob
    Chiluba, Brian Chanda
    PAN AFRICAN MEDICAL JOURNAL, 2021, 39
  • [37] A Genome-Wide Association Study Identifies KNG1 as a Genetic Determinant of Plasma Factor XI Level and Activated Partial Thromboplastin Time
    Sabater-Lleal, Maria
    Martinez-Perez, Angel
    Buil, Alfonso
    Folkersen, Lasse
    Carlos Souto, Juan
    Bruzelius, Maria
    Borrell, Montserrat
    Odeberg, Jacob
    Silveira, Angela
    Eriksson, Per
    Almasy, Laura
    Hamsten, Anders
    Manuel Soria, Jose
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (08) : 2008 - 2016
  • [38] Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics
    Trucco, M.
    Lehmann, C. U.
    Mollenkopf, N.
    Streiff, M. B.
    Takemoto, C. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 788 - 794
  • [39] Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent
    Wilmot, Helen V.
    Gray, Elaine
    HAEMOPHILIA, 2018, 24 (05) : E363 - E368
  • [40] Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis
    Gessoni, Gianluca
    Valverde, Sara
    BLOOD COAGULATION & FIBRINOLYSIS, 2007, 18 (07) : 603 - 610